Herbs · Ashwagandha

Ayurvedic Vata-pacifying and Rasayana interventions improve visual acuity and anatomical resolution in CSR patients with Vata Prakriti

Three CSR patients (two males aged 65 and 46, one female aged 40) with confirmed Vata Prakriti received a standardized Ayurvedic regimen including Ashwagandha, Punarnavadi Kashaya, Tiktaka Ghrita, Kalyanaka Ghrita, Triphala Churna, and local ocular therapies. All three showed marked improvement in visual acuity and complete anatomical resolution of macular fluid on OCT within 4-17 months, with no recurrence over 1 year follow-up.

1 min readUpdated Aug 25, 20260 RCTsView structured evidence →
Evidence Score32/100
Human RCT☆☆☆☆☆
Meta-analysis☆☆☆☆☆
Mechanism★★★★★
Safety★★★★
Confidencelow

This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.

Ayurvedic Vata-pacifying and Rasayana interventions improve visual acuity and anatomical resolution in CSR patients with Vata Prakriti The current body of evidence comprises 1 study. EvidenceHub rates the overall confidence at 32/100 (low).

The Claim

Ayurvedic Vata-pacifying and Rasayana interventions improve visual acuity and anatomical resolution in CSR patients with Vata Prakriti

This conclusion is most relevant to: Three patients (two males aged 65 and 46, one female aged 40) diagnosed with Central Serous Retinopathy (CSR) and confirmed as Vata Prakriti through a standardized questionnaire.

What the Research Shows

The conclusion draws on 1 linked study. Highlights from the cited literature:

  • Prakriti phenotyping in Central Serous Retinopathy (CSR): case series on Ayurvedic therapeutic outcomes in Vata individuals. (Frontiers in medicine, 2026) —

How It Works

The proposed biological pathway:

  • Vata Prakriti individuals have hyperactivity, anxiety, and autonomic instability predisposing to Vata imbalance
  • Ayurvedic interventions pacify Vata and provide Rasayana (rejuvenative) effects
  • Local ocular therapies reduce inflammation and support retinal healing
  • Result: Resolution of macular fluid and improved visual function

Who Might Benefit

Evidence fit by population:

  • Three patients (two males aged 65 and 46, one female aged 40) diagnosed with Central Serous Retinopathy (CSR) and confirmed as Vata Prakriti through a standardized questionnaire

Limitations & Caveats

Important context when interpreting this evidence:

  • Very small sample size (n=3) limits generalizability
  • No control group or blinding, making it a case series with low internal validity
  • Lack of standardized dosing for each intervention component

Frequently Asked Questions

What is Central Serous Retinopathy (CSR)?

CSR is a retinal disorder involving serous detachment of the neurosensory retina, often linked to psychological stress and Type A personality traits.

How was Vata Prakriti determined in this study?

Vata Prakriti was confirmed through a standardized questionnaire assessing constitutional traits like hyperactivity, anxiety, and autonomic instability.

What were the main Ayurvedic treatments used?

The regimen included oral Ashwagandha, Punarnavadi Kashaya, Tiktaka Ghrita, Kalyanaka Ghrita, Triphala Churna, plus local therapies like Shiro Pichu, Pratimarsha Nasya, and Anjana Karma.

How long did it take for patients to recover?

Complete anatomical resolution of macular fluid occurred within 4 to 17 months, with no recurrence over 1 year of follow-up.

References

  1. 1.K S, G G. “Prakriti phenotyping in Central Serous Retinopathy (CSR): case series on Ayurvedic therapeutic outcomes in Vata individuals..” Frontiers in medicine, 2026. PMID: 41488094 DOI: 10.3389/fmed.2025.1722235
Disclaimer: This article is auto-generated from structured research data for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.